reMYND NV is a dynamic biotech company located in Leuven (Belgium) that actively drives R&D in the field of protein misfolding diseases, among others Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company consists of two independently managed units. The Drug Discovery and Development Unit focuses on disease-modifying treatments for among others AD and PD (counteracting TAU and aSyn toxicity, respectively). The Contract Research Unit offers extensive experience in the testing of experimental Alzheimer therapies in its unique and proprietary transgenic mouse models. For more information please visit www.remynd.com Alternatively, please contact Koen De Witte (Managing Director - pipeline@remynd.com) to hear more about reMYND's pipeline or Bart Roucourt (Manager Contact Research - cro@remynd.com) to get more information on reMYND's Contract Research Offering.